Literature DB >> 19628648

Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated?

Willem-Jan Welboren1, Fred C G J Sweep, Paul N Span, Hendrik G Stunnenberg.   

Abstract

The estrogen receptor alpha (ERalpha) is a ligand-dependent transcription factor that regulates a large number of genes in many different target tissues and is important in the development and progression of breast cancer. ERalpha-mediated transcription is a complex process regulated at many different levels. The interplay between ligand, receptor, DNA sequence, cofactors, chromatin context, and post-translational modifications culminates in transcriptional regulation by ERalpha. Recent technological advances have allowed the identification of ERalpha target genes on a genome-wide scale. In this review, we provide an overview of the progress made in our understanding of the different levels of regulation mediated by ERalpha. We discuss the recent advances in the identification of the ERalpha-binding sites and target gene network and their clinical applications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628648     DOI: 10.1677/ERC-09-0086

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  60 in total

1.  Functional variable number of tandem repeats variation in the promoter of proto-oncogene PTTG1IP is associated with risk of estrogen receptor-positive breast cancer.

Authors:  Chan Xiang; Haidong Gao; Lei Meng; Zhaoyu Qin; Rong Ma; Yang Liu; Yan Jiang; Chengxue Dang; Li Jin; Fuchu He; Haijian Wang
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

Review 2.  Estrogen receptors and human disease: an update.

Authors:  Katherine A Burns; Kenneth S Korach
Journal:  Arch Toxicol       Date:  2012-05-31       Impact factor: 5.153

Review 3.  Allosteric pathways in nuclear receptors - Potential targets for drug design.

Authors:  Elias J Fernandez
Journal:  Pharmacol Ther       Date:  2017-10-31       Impact factor: 12.310

4.  Changes in Gene Expression and Estrogen Receptor Cistrome in Mouse Liver Upon Acute E2 Treatment.

Authors:  Gaëlle Palierne; Aurélie Fabre; Romain Solinhac; Christine Le Péron; Stéphane Avner; Françoise Lenfant; Coralie Fontaine; Gilles Salbert; Gilles Flouriot; Jean-François Arnal; Raphaël Métivier
Journal:  Mol Endocrinol       Date:  2016-05-10

Review 5.  Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology.

Authors:  Kazuhiro Ikeda; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

6.  Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer.

Authors:  Zachary E Stine; David M McGaughey; Seneca L Bessling; Shengchao Li; Andrew S McCallion
Journal:  Hum Mol Genet       Date:  2011-07-07       Impact factor: 6.150

7.  Liganded ERα Stimulates the E3 Ubiquitin Ligase Activity of UBE3C to Facilitate Cell Proliferation.

Authors:  Maiko Okada; Fumiaki Ohtake; Hiroyuki Nishikawa; Wenwen Wu; Yasushi Saeki; Keiji Takana; Tomohiko Ohta
Journal:  Mol Endocrinol       Date:  2015-09-21

8.  Epigenetic regulation of estrogen receptor alpha gene expression in the mouse cortex during early postnatal development.

Authors:  Jenne M Westberry; Amanda L Trout; Melinda E Wilson
Journal:  Endocrinology       Date:  2009-12-04       Impact factor: 4.736

9.  A semi-parametric Bayesian model for unsupervised differential co-expression analysis.

Authors:  Johannes M Freudenberg; Siva Sivaganesan; Michael Wagner; Mario Medvedovic
Journal:  BMC Bioinformatics       Date:  2010-05-07       Impact factor: 3.169

10.  Expression of G protein-coupled estrogen receptor in irritable bowel syndrome and its clinical significance.

Authors:  Bin Qin; Lei Dong; Xiaoyan Guo; Jiong Jiang; Yangxin He; Xiaoyan Wang; Lu Li; Juhui Zhao
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.